A Phase I Study of BPM31510 Plus Vitamin K in Subjects With Glioblastoma That Has Recurred on a Bevacizumab-Containing Regimen

Trial Profile

A Phase I Study of BPM31510 Plus Vitamin K in Subjects With Glioblastoma That Has Recurred on a Bevacizumab-Containing Regimen

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs Ubidecarenone (Primary)
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Feb 2017 According to a Berg Pharma media release, trial is being conducted by principal Dr. Lawrence Recht at the Stanford University School of Medicine.
    • 18 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top